Represented Collegium Pharmaceutical, Inc. in Hatch-Waxman patent litigation concerning a Section 505(b)(2) application for a pain treatment drug. Obtained summary judgment of non-infringement. Purdue Pharma L.P. v. Collegium Pharm., Inc., 335 F. Supp. 3d 149 (D. Mass. 2018).

Represented Collegium Pharmaceutical, Inc. in Hatch-Waxman patent litigation concerning the filing of its Supplemental NDA for a pain treatment drug. Argued motion to dismiss and obtained full dismissal of lawsuit. Purdue Pharma L.P. v. Collegium Pharm., Inc., No. 17-cv-11923 (D. Mass. 2018).

Represented Collegium Pharmaceutical Inc. in a Post-Grant Review at the PTAB seeking cancellation of patent directed to a pain management drug. Collegium Pharmaceutical Inc. v. Purdue Pharma L.P., PGR2018-00048 (filed March 13, 2018).   

Defended Club Car, LLC in IPRs brought by competitor Yamaha Golf Car Company. Obtained complete victory in each of the four IPRs. PTAB ruled that no patent claim was invalid as anticipated or obvious. Yamaha Golf Car Co. v. Club Car, LLC, IPR2017-02141, et seq. (Final Written Decision Apr. 2, 2019).

Represented Medtronic in thirteen IPRs challenging five patents directed to guide extension catheters. Medtronic, Inc. v. Teleflex Innovations S.À.R.L., IPR2020-00126, et seq. (filed Nov. 12, 2019).

Represented Upsher-Smith Laboratories in Hatch-Waxman litigation concerning five Orange Book listed patents for the acne drug, Absorica.^® Sun Pharmaceutical Industries, Inc. v. Upsher-Smith Laboratories, No. 19-cv-02546 (D.N.J. 2019).

Represented Zenara Pharma Private Limited in Hatch-Waxman litigation concerning four Orange Book listed patents for a Gaucher disease drug, Cerdelga.^® Genzyme Corp. v. Zenara Pharma Private Limited, No. 18-cv-01795 (D. Del. 2018).

Represented Collegium Pharmaceutical Inc. in brand-on-brand pharmaceutical litigation relating to the sale of Nucynta.^® Purdue Pharma L.P. v. Collegium NF, LLC., No. 18-cv-00226 (D. Del. 2018).

Lead counsel in action that obtained habeas corpus relief for detained individual. Abdulkadir v. Sessions, No. 18-cv-2353 (NEB/HB), 2018 U.S. Dist. LEXIS 219431 (D. Minn. Nov. 13, 2018).

Represented Teva Pharmaceuticals in Hatch-Waxman litigation involving seven Orange Book listed patents for the extended-release Alzheimer’s drug, Namenda XR^®.  Part of a team that invalidated six patents, on indefiniteness grounds, prior to trial. Forest Labs., Inc. v. Teva Pharms. USA, Inc., C.A. No. 14-121, 2016 U.S. Dist. LEXIS 322 (D. Del. Jan. 5, 2016), aff’d 716 F. App’x 987 (Fed. Cir. 2017). Upon completion of a four-day bench trial on the remaining patent, the matter settled for value. (Prior to joining Robins Kaplan LLP.)

Represented Teva Pharmaceuticals in Hatch-Waxman litigation concerning its ANDA for a pain management drug. After an eight-day bench trial, the court found each asserted patent was either not infringed and/or invalid. Purdue Pharma L.P. v. Teva Pharms., USA, Inc. (In re OxyContin Antitrust Litig.), 994 F. Supp. 2d 367 (S.D.N.Y. 2014), aff’d sub nom. Purdue Pharma L.P. v. Epic Pharma, LLC, 811 F.3d 1345 (Fed. Cir. 2016). (Prior to joining Robins Kaplan LLP.)   

Represented Rust-Oleum in a trademark matter in the District of Minnesota. Was part of a team that defeated a motion for preliminary injunction.  Plasti-Dip Int’l Inc. v. Rust-Oleum Brands Co., Civil No. 14-1831, 2014 U.S. Dist. LEXIS 174560 (D. Minn. Dec. 16, 2014).  (Prior to joining Robins Kaplan LLP.)              

Represented Breckenridge Pharmaceuticals in a Hatch-Waxman litigation relating to a cachexia drug, Megace ES^®. Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc., No. 13-cv-01114 (D. Del.) (Prior to joining Robins Kaplan LLP.)

• Member of the Grants Committee for the Minnesota Federal Bar Association (2016-2018)
• Chair of the Intellectual Property Practice Group for the Minnesota Federal Bar Association (2015-2016)